Please login to the form below

Not currently logged in
Email:
Password:

Nimbus Therapeutics

This page shows the latest Nimbus Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Roche's O’Day swaps big pharma for big biotech

Roche's O’Day swaps big pharma for big biotech

with Sangamo to use its zinc finger gene-editing platform for drug discovery, and a $1.2bn deal to acquire Nimbus Therapeutics and its non-alcoholic steatohepatitis (NASH) candidate selonsertib.

Latest news

  • Gilead chalks up trial success for new NASH drug Gilead chalks up trial success for new NASH drug

    Along with selonsertib, Gilead is also developing an FXR agonist called GS-9674 in phase I trials and acquired a wholly-owned subsidiary of Nimbus Therapeutics for $1.2bn earlier this ... Allergan has been building a pipeline of candidates through a

  • Torrid times at Gilead lead to calls for a major M&A deal Torrid times at Gilead lead to calls for a major M&A deal

    The company has a history of making successful bolt-on acquisitions - adding its HIV blockbusters with the purchase of Triangle Therapeutics in 2003 and hepatitis portfolio by buying Pharmasset in 2011 - ... Smaller deals - including a $1.2bn deal for

  • FDA panel backs Intercept's rare liver disease drug FDA panel backs Intercept's rare liver disease drug

    As a NASH therapy Ocaliva could face competition from Gilead Sciences' simtuzumab (in phase II), an earlier stage acetyl-CoA carboxylase (ACC) inhibitor candidate just acquired from Nimbus Therapeutics, as well

  • Gilead boosts liver disease pipeline with $1.2bn acquisition Gilead boosts liver disease pipeline with $1.2bn acquisition

    Also has combination HIV therapy Descovy approved by FDA. Gilead Sciences boosted its pipeline of treatments for liver disease by buying a subsidiary of Nimbus Therapeutics in a deal that could ... In addition to the upfront payment of $400m, Nimbus

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest appointments

  • ARC names chairman and member of the board ARC names chairman and member of the board

    Iwicki is executive chairman of the board of directors of Kala Pharmaceuticals and sits on the boards of Nimbus Therapeutics and Taris Biomedical. ... He was president and CEO of Civitas Therapeutics until late 2014 and prior to this, held the same

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics